鲁抗医药：控股子公司赛特公司获得非那雄胺片药品注册证书

Core Viewpoint - The approval of Finasteride tablets by the National Medical Products Administration is a significant milestone for the company, enhancing its product portfolio and addressing market demand [1] Group 1: Product Approval - The company's subsidiary, Sait Company, received a drug registration certificate for Finasteride tablets, classified as a Category 4 generic drug [1] - The drug has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 2: Product Specifications and Uses - The 1mg specification is intended for the treatment of male pattern baldness, promoting hair growth and preventing further hair loss [1] - The 5mg specification is used for treating and controlling benign prostatic hyperplasia (BPH), helping to reduce prostate size and improve urinary flow and related symptoms [1] Group 3: Research and Development Investment - Sait Company has invested approximately RMB 3.5 million in research and development for this product [1] Group 4: Market Impact - The approval is expected to positively impact the company's product structure optimization, maintain stable production capacity, and meet market demand [1] - However, the production and sales of the drug are subject to uncertainties influenced by policies and market conditions [1]